P/B
1
Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
$311.1M
Market Cap • 11/10/2026
1998
(28 years)
Founded
2006
(20 years ago)
IPO
NYSE
Listing Exchange
United States
Country
Valuation
P/S
0,5
P/EBITDA
—
P/OCF
1,6
P/FCF
1,7
P/E
—
BVPS
6,1
EPS
—
Market Cap
Market Cap
311,1M
EV
643,1M
EV/Revenue
1
EV/EBITDA
-7,6
EV/EBIT
-3,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
7,9%
Total Yield
7,9%
Payout
0%
Retained Earnings
-365,9M
Profitability
Gross Margin
48,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
6,3%
Capex/Revenue
1,8%
Capex/D&A
12,2%
Capex/OCF
5,8%
SBC/OCF
9,1%
% PPE
17,6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-17,3%
CAGR OCF 5Y
-3,4%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
4,6
Quick Ratio
2,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!